Landec Corporation Reports First Quarter Fiscal Year 2023 Results
Lifecore segment revenues increased 8.0% to
Lifecore segment EBITDA increased 8.1% to
Reiterates fiscal 2023 full year guidance for Lifecore
Corporate rebranding to Lifecore Biomedical continues to progress
CEO COMMENTS:
LANDEC FISCAL FIRST QUARTER 2023 BUSINESS HIGHLIGHTS:
As previously reported, on
- Consolidated revenues of
$43.4 million , an increase of 4.1% year-over-year - Consolidated gross profit of
$5.8 million , a decrease of 44.2% year-over-year, primarily due to cost inflation atCuration Foods . - Consolidated net loss from continuing operations of
$12.1 million , which includes$2.7 million of restructuring and other non-recurring charges such as legal expenses, both net of tax - Consolidated adjusted EBITDA of
$(1.1) million , compared to$2.5 million in the prior year period - Lifecore segment EBITDA of
$2.5 million , compared to$2.3 million in the prior year period, an increase of 8.1% year-over-year
CONSOLIDATED FISCAL FIRST QUARTER 2023 RESULTS:
Fiscal first quarter 2023 results compared to fiscal first quarter 2022 are as follows:
| (Unaudited and in thousands, except per-share data) | Three Months Ended | Change | ||||||||||||
| Amount | % | |||||||||||||
| Revenues | $ | 43,355 | $ | 41,632 | $ | 1,723 | 4 | % | ||||||
| Gross profit | 5,821 | 10,435 | (4,614 | ) | (44) | % | ||||||||
| Net loss | (12,064 | ) | (7,633 | ) | (4,431 | ) | (58) | % | ||||||
| Adjusted net loss | (9,400 | ) | (5,472 | ) | (3,928 | ) | (72) | % | ||||||
| Diluted net loss per share | (0.41 | ) | (0.26 | ) | (0.15 | ) | (58) | % | ||||||
| Adjusted diluted net loss per share* | (0.32 | ) | (0.19 | ) | (0.13 | ) | (68) | % | ||||||
| EBITDA* | (3,735 | ) | (2,023 | ) | (1,712 | ) | (85) | % | ||||||
| Adjusted EBITDA* | (1,057 | ) | 2,450 | (3,507 | ) | (143) | % | |||||||
* See “Non-GAAP Financial Information” at the end of this release for more information and for a reconciliation of certain financial information.
Revenues increased
Gross profit decreased
Net loss from continuing operations increased
SEGMENT RESULTS:
Lifecore Segment:
| (Unaudited and in thousands) |
Three Months Ended | Change | |||||||||||
2022 |
2021 |
Amount | % | ||||||||||
| Revenue: | |||||||||||||
| CDMO | $ | 18,247 | $ | 17,789 | $ | 458 | 3 | % | |||||
| Fermentation | 5,456 | 4,163 | 1,293 | 31 | % | ||||||||
| Total revenue | $ | 23,703 | $ | 21,952 | $ | 1,751 | 8 | % | |||||
Lifecore is the Company’s CDMO business focused on product development and manufacturing of sterile injectable products. Lifecore continues to expand its presence in the robust CDMO marketplace by utilizing its specialized capabilities to partner with and provide value-added services to biopharmaceutical and medical device companies. Lifecore continues to drive growth and profitability with a focus on building its business development pipeline, maximizing capacity and advancing product commercialization for innovative new therapies that improve patients’ lives.
In the fiscal first quarter 2023, Lifecore realized total revenues of
Lifecore's development pipeline remained at 24 active development programs under contract as of the end of fiscal 2023 first quarter. These projects are delineated as follows: early phase or proof of concept (5), Phase 1 and Phase 2 clinical development (11), and Phase 3 clinical development or scale-up/commercial validation activity (8). Lifecore currently manufactures 26 commercial products for 13 clients, which remains unchanged from fiscal fourth quarter 2022.
Curation Foods Segment:
| (Unaudited and in thousands) |
Three Months Ended | Change | ||||||||||||
| Amount | % | |||||||||||||
| Revenue: | ||||||||||||||
| Olive oil and vinegars | $ | 2,559 | $ | 2,340 | $ | 219 | 9 | % | ||||||
| Avocado products | 17,093 | 16,962 | 131 | 1 | % | |||||||||
| Technology | — | 378 | (378 | ) | (100) | % | ||||||||
| Total revenue | $ | 19,652 | $ | 19,680 | $ | (28 | ) | — | % | |||||
CASH FLOW & BALANCE SHEET
Cash used in operations was
The Company had cash and cash equivalents of
FISCAL 2023 OUTLOOK:
The Company is reiterating its full year fiscal 2023 guidance for its Lifecore and Corporate segments. Guidance metrics are provided below with growth figures that are compared to fiscal 2022:
- Lifecore segment revenue: range of
$122 million to$126 million (+12% to +15%) - Lifecore segment adjusted EBITDA: range of
$31.0 million to$32.5 million (+7% to +12%) - Other segment (corporate expense): range of
($7.0) million to($7.5) million - Consolidated adjusted EBITDA*: range of
$23.5 million to$25.5 million
*Reflects Lifecore segment, net of Other segment; assumes zero contribution from the
Conference Call
The live webcast can be accessed via Landec’s website on the Investor Events & Presentations page. The webcast will be available for 30 days.
Date:
Time:
Webcast link: http://ir.landec.com/events.cfm
To participate in the conference call via telephone, dial toll-free: (877) 407-3982 or (201) 493-6780. Please call the conference telephone number 5-10 minutes prior to the start time so the operator can register your name and organization.
A replay of the call will be available through
About
Non-GAAP Financial Information
This press release contains non-GAAP financial information, including with respects to EBITDA, adjusted EBITDA, Lifecore segment adjusted EBITDA,
The Company has disclosed these non-GAAP financial measures to supplement its consolidated financial statements presented in accordance with GAAP. These non-GAAP financial measures exclude/include certain items that are included in the Company’s results reported in accordance with GAAP. Management believes these non-GAAP financial measures provide useful additional information to investors about trends in the Company’s operations and are useful for period-over-period comparisons. These non-GAAP financial measures should not be considered in isolation or as a substitute for the comparable GAAP measures. In addition, these non-GAAP financial measures may not be the same as similar measures provided by other companies due to the potential differences in methods of calculation and items being excluded/included. These non-GAAP financial measures should be read in conjunction with the Company’s consolidated financial statements presented in accordance with GAAP.
Important Cautions Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding future events and our future results that are subject to the safe harbor created under the Private Securities Litigation Reform Act of 1995 and other safe harbors under the Securities Act of 1933 and the Securities Exchange Act of 1934. Words such as “anticipate”, “estimate”, “expect”, “project”, “plan”, “intend”, “believe”, “may”, “might”, “will”, “should”, “can have”, “likely” and similar expressions are used to identify forward-looking statements. All forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially, including such factors among others, as the timing and expenses associated with operations, the ability to achieve acceptance of the Company’s new products in the market place, weather conditions that can affect the supply and price of produce, government regulations affecting our business, the timing of regulatory approvals, uncertainties related to COVID-19 and the impact of our responses to it, the ability to successfully integrate
CONSOLIDATED CONDENSED BALANCE SHEETS
(In thousands, except par value)
| (Unaudited) | |||||||
| ASSETS | |||||||
| Current Assets: | |||||||
| Cash and cash equivalents | $ | 4,222 | $ | 1,643 | |||
| Accounts receivable, less allowance for credit losses | 40,934 | 48,172 | |||||
| Inventories | 64,285 | 66,845 | |||||
| Prepaid expenses and other current assets | 7,157 | 7,052 | |||||
| Total Current Assets | 116,598 | 123,712 | |||||
| Property and equipment, net | 129,024 | 130,435 | |||||
| Operating lease right-of-use assets | 8,229 | 8,580 | |||||
| 13,881 | 13,881 | ||||||
| Trademarks/tradenames, net | 8,400 | 8,400 | |||||
| Customer relationships, net | 6,875 | 7,150 | |||||
| Other assets | 2,793 | 3,002 | |||||
| Total Assets | $ | 285,800 | $ | 295,160 | |||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
| Current Liabilities: | |||||||
| Accounts payable | $ | 16,366 | $ | 15,802 | |||
| Accrued compensation | 6,373 | 9,238 | |||||
| Other accrued liabilities | 7,832 | 7,647 | |||||
| Current portion of lease liabilities | 5,021 | 5,026 | |||||
| Deferred revenue | 803 | 919 | |||||
| Line of credit | 44,000 | 40,000 | |||||
| Current portion of long-term debt, net | 2,704 | 599 | |||||
| Total Current Liabilities | 83,099 | 79,231 | |||||
| Long-term debt, net | 95,865 | 97,579 | |||||
| Long-term lease liabilities | 9,447 | 9,983 | |||||
| Deferred taxes, net | 291 | 232 | |||||
| Other non-current liabilities | 199 | 190 | |||||
| Total Liabilities | 188,901 | 187,215 | |||||
| Stockholders’ Equity: | |||||||
| Common stock, |
30 | 30 | |||||
| Additional paid-in capital | 168,070 | 167,352 | |||||
| Retained earnings (accumulated deficit) | (70,915 | ) | (58,851 | ) | |||
| Accumulated other comprehensive loss | (286 | ) | (586 | ) | |||
| Total Stockholders’ Equity | 96,899 | 107,945 | |||||
| Total Liabilities and Stockholders’ Equity | $ | 285,800 | $ | 295,160 | |||
CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME
(Unaudited)
(In thousands, except per share amounts)
| Three Months Ended | ||||||||
| Product sales | $ | 43,355 | $ | 41,632 | ||||
| Cost of product sales | 37,534 | 31,197 | ||||||
| Gross profit | 5,821 | 10,435 | ||||||
| Operating costs and expenses: | ||||||||
| Research and development | 2,048 | 1,873 | ||||||
| Selling, general and administrative | 10,883 | 9,470 | ||||||
| Restructuring costs | 1,047 | 1,834 | ||||||
| Total operating costs and expenses | 13,978 | 13,177 | ||||||
| Operating loss | (8,157 | ) | (2,742 | ) | ||||
| Interest income | 15 | 27 | ||||||
| Interest expense | (3,678 | ) | (6,678 | ) | ||||
| Other (expense) income, net | (180 | ) | 109 | |||||
| Net loss before tax | (12,000 | ) | (9,284 | ) | ||||
| Income tax benefit (expense) | (64 | ) | 1,651 | |||||
| Net loss from continuing operations | $ | (12,064 | ) | $ | (7,633 | ) | ||
| Discontinued operations: | ||||||||
| Loss from discontinued operations | $ | — | $ | (2,305 | ) | |||
| Income tax benefit | — | 461 | ||||||
| Loss from discontinued operations, net of tax | — | (1,844 | ) | |||||
| Net loss | (12,064 | ) | (9,477 | ) | ||||
| Diluted net loss per share | ||||||||
| Loss from continuing operations | $ | (0.41 | ) | $ | (0.26 | ) | ||
| Loss from discontinued operations | — | (0.06 | ) | |||||
| Total diluted net loss per share | $ | (0.41 | ) | $ | (0.32 | ) | ||
| Shares used in diluted per share computation | 29,577 | 29,424 | ||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited and in thousands)
| Three Months Ended | |||||||
| Cash flows from operating activities: | |||||||
| Net loss | $ | (12,064 | ) | $ | (9,477 | ) | |
| Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | |||||||
| Depreciation, amortization of intangibles, debt costs, and right-of-use assets | 5,009 | 5,054 | |||||
| Gain on disposal of property and equipment related to restructuring, net | — | (92 | ) | ||||
| Deferred taxes | 43 | (2,138 | ) | ||||
| Stock-based compensation expense | 785 | 620 | |||||
| Gain on sale of BreatheWay | (2,108 | ) | — | ||||
| Net loss on disposal of property and equipment held and used | — | 16 | |||||
| Provision (benefit) for expected credit losses | — | 60 | |||||
| Other, net | (18 | ) | (70 | ) | |||
| Changes in current assets and current liabilities: | |||||||
| Accounts receivable, net | 7,238 | 7,997 | |||||
| Inventories | 2,560 | 248 | |||||
| Prepaid expenses and other current assets | (761 | ) | (2,697 | ) | |||
| Accounts payable | 581 | 1,517 | |||||
| Accrued compensation | (2,865 | ) | (3,131 | ) | |||
| Other accrued liabilities | 183 | 2,838 | |||||
| Deferred revenue | (116 | ) | 86 | ||||
| Net cash provided by (used in) operating activities | (1,533 | ) | 831 | ||||
| Cash flows from investing activities: | |||||||
| Proceeds from sale of BreatheWay, net | 3,135 | — | |||||
| Sale of investment in non-public company | — | 45,100 | |||||
| Purchases of property and equipment | (2,929 | ) | (7,913 | ) | |||
| Proceeds from sales of property and equipment | — | 1,082 | |||||
| Net cash provided by investing activities | 206 | 38,269 | |||||
| Cash flows from financing activities: | |||||||
| Payments on long-term debt | (27 | ) | (41,388 | ) | |||
| Proceeds from lines of credit | 4,000 | 8,000 | |||||
| Payments on lines of credit | — | (5,000 | ) | ||||
| Payments for debt issuance costs | — | (132 | ) | ||||
| Taxes paid by Company for employee stock plans | (67 | ) | (428 | ) | |||
| Net cash provided by (used in) financing activities | 3,906 | (38,948 | ) | ||||
| Net increase in cash, cash equivalents and restricted cash | 2,579 | 152 | |||||
| Cash and cash equivalents and restricted cash, beginning of period | 1,643 | 1,295 | |||||
| Cash and cash equivalents and restricted cash, end of period | $ | 4,222 | $ | 1,447 | |||
| Supplemental disclosure of non-cash investing and financing activities: | |||||||
| Purchases of property and equipment on trade vendor credit | $ | 2,243 | $ | 1,994 | |||
SEGMENT RESULTS
(Unaudited and in thousands)
| (Unaudited and in thousands) |
Three Months Ended | Change | ||||||||||||||
| Amount | % | |||||||||||||||
| Revenues: | ||||||||||||||||
| $ | 19,652 | $ | 19,680 | $ | (28 | ) | — | % | ||||||||
| Lifecore | 23,703 | 21,952 | 1,751 | 8 | % | |||||||||||
| Total revenues | $ | 43,355 | $ | 41,632 | $ | 1,723 | 4 | % | ||||||||
| Gross profit: | ||||||||||||||||
| $ | (280 | ) | $ | 4,671 | $ | (4,951 | ) | N/M | ||||||||
| Lifecore | 6,101 | 5,764 | 337 | 6 | % | |||||||||||
| Total gross profit | $ | 5,821 | $ | 10,435 | $ | (4,614 | ) | (44) | % | |||||||
| Net (loss) income from continuing operations: | ||||||||||||||||
| $ | (3,374 | ) | $ | 167 | $ | (3,541 | ) | N/M | ||||||||
| Lifecore | 502 | 580 | (78 | ) | (13) | % | ||||||||||
| Other | (9,192 | ) | (8,380 | ) | (812 | ) | (10) | % | ||||||||
| Total net loss from continuing operations | $ | (12,064 | ) | $ | (7,633 | ) | $ | (4,431 | ) | (58) | % | |||||
| Loss from discontinued operations, net of tax: | ||||||||||||||||
| $ | — | $ | (1,844 | ) | $ | 1,844 | (100) | % | ||||||||
| Net loss | $ | (12,064 | ) | $ | (9,477 | ) | $ | (2,587 | ) | (27) | % | |||||
| EBITDA: | ||||||||||||||||
| $ | (1,618 | ) | $ | (1,329 | ) | $ | (289 | ) | (22) | % | ||||||
| Lifecore | 2,416 | 2,290 | 126 | 6 | % | |||||||||||
| Other | (4,533 | ) | (2,984 | ) | (1,549 | ) | (52) | % | ||||||||
| Total EBITDA | $ | (3,735 | ) | $ | (2,023 | ) | $ | (1,712 | ) | (85) | % | |||||
Non-GAAP Financial Information and Reconciliations
EBITDA and adjusted EBITDA are non-GAAP financial measures. We define EBITDA as earnings before interest, income tax expense (benefit), and depreciation and amortization. We define adjusted EBITDA as EBITDA before certain restructuring and other non-recurring charges. See “Non-GAAP Financial Information” above for further information regarding the Company’s use of non-GAAP financial measures.
| (Unaudited and in thousands) | Lifecore | Other | Total | |||||||||||||
| Three months ended |
||||||||||||||||
| Net (loss) income | $ | 502 | $ | (3,374 | ) | $ | (9,192 | ) | $ | (12,064 | ) | |||||
| Interest expense, net of interest income | (15 | ) | — | 3,678 | 3,663 | |||||||||||
| Income tax (benefit) expense | 158 | (1,065 | ) | 971 | 64 | |||||||||||
| Depreciation and amortization | 1,771 | 2,821 | 10 | 4,602 | ||||||||||||
| Total EBITDA | 2,416 | (1,618 | ) | (4,533 | ) | (3,735 | ) | |||||||||
| Restructuring and other non-recurring charges (1) | 60 | (65 | ) | 2,683 | 2,678 | |||||||||||
| Loss from discontinued operations, net of tax | — | — | — | — | ||||||||||||
| Total adjusted EBITDA | $ | 2,476 | $ | (1,683 | ) | $ | (1,850 | ) | $ | (1,057 | ) | |||||
| Three Months Ended |
||||||||||||||||
| Net (loss) income | $ | 580 | $ | (1,677 | ) | $ | (8,380 | ) | $ | (9,477 | ) | |||||
| Interest expense and loss on debt refinancing, net of interest income | (20 | ) | 137 | 6,534 | 6,651 | |||||||||||
| Income tax (benefit) expense | 183 | (670 | ) | (1,164 | ) | (1,651 | ) | |||||||||
| Depreciation and amortization | 1,547 | 881 | 26 | 2,454 | ||||||||||||
| Total EBITDA | 2,290 | (1,329 | ) | (2,984 | ) | (2,023 | ) | |||||||||
| Restructuring and other non-recurring charges | — | 468 | 2,161 | 2,629 | ||||||||||||
| Loss from discontinued operations, net of tax | — | 1,844 | — | 1,844 | ||||||||||||
| Total adjusted EBITDA | $ | 2,290 | $ | 983 | $ | (823 | ) | $ | 2,450 | |||||||
(1) During fiscal year 2020, the Company announced a restructuring plan to drive enhanced profitability, focus the business on its strategic assets, and redesign the organization to be the appropriate size to compete and thrive. This included a reduction-in-force, a reduction in leased office spaces, and the sale of non-strategic assets. Related to these continued activities, in the first quarter of fiscal year 2023, the Company incurred (1)
Contact Information:
Investor Relations
(646) 277-1263
jeff.sonnek@icrinc.com
Source: Landec Corporation